$885M IBS Drug Verdict Tests Pay-For-Delay Limits
A federal jury in Massachusetts returned a $885 million verdict against Takeda Pharmaceuticals Co., finding that Takeda entered into an anticompetitive patent settlement that compensated a generic manufacturer to delay launching...To view the full article, register now.
Already a subscriber? Click here to view full article